Share Name Share Symbol Market Type Share ISIN Share Description
International Biotechnology Trust Plc LSE:IBT London Ordinary Share GB0004559349 ORD 25P
  Price Change % Change Share Price Shares Traded Last Trade
  -17.00 -2.23% 745.00 71,185 16:35:07
Bid Price Offer Price High Price Low Price Open Price
742.00 748.00 750.00 740.00 750.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 1.13 -2.06 -5.79 304
Last Trade Time Trade Type Trade Size Trade Price Currency
16:21:28 O 400 743.50 GBX

International Biotechnol... (IBT) Latest News (1)

More International Biotechnol... News
International Biotechnol... Investors    International Biotechnol... Takeover Rumours

International Biotechnol... (IBT) Discussions and Chat

International Biotechnol... Forums and Chat

Date Time Title Posts
16/12/202011:30International Biotechnolgy Trust330
29/4/201909:54International Boitechnology Trust148
21/10/200103:31"Biotech names selling on air"2
28/12/200012:08Soros buys Int.Biotech stake5
17/7/200017:11Int Biotech1

Add a New Thread

International Biotechnol... (IBT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all International Biotechnol... trades in real-time

International Biotechnol... (IBT) Top Chat Posts

International Biotechnol... Daily Update: International Biotechnology Trust Plc is listed in the Equity Investment Instruments sector of the London Stock Exchange with ticker IBT. The last closing price for International Biotechnol... was 762p.
International Biotechnology Trust Plc has a 4 week average price of 740p and a 12 week average price of 740p.
The 1 year high share price is 862p while the 1 year low share price is currently 451p.
There are currently 40,837,817 shares in issue and the average daily traded volume is 79,520 shares. The market capitalisation of International Biotechnology Trust Plc is £303,016,602.14.
speedsgh: Dividend Declaration - HTTPS:// At the Annual General Meeting held on 15 December 2020, Shareholders approved the Company's dividend policy of making dividend payments, equivalent to 4 per cent. of the Company's Net Asset Value as at the last day of the preceding financial year (31 August), through two equal semi-annual distributions. The Directors have today declared the first Interim Dividend for the period ending 31 August 2021 in an amount of 14.2p per Ordinary Share. The first Interim Dividend will be payable on Friday, 29 January 2021 to holders of Ordinary Shares on the Register at the close of business on Tuesday, 29 December 2020 (ex-dividend Thursday, 24 December 2020).
shieldbug: Not so pleased to see how they calculate the dividend though. The 4% is calculated once a year and divided into two payments. So we don't get 2% of the mid July price.
shieldbug: This year IBT bought back about £1m of shares (172,546 shares) at an average price of £5.82 and have just issued 75,000 shares at £7.94. Rarely see great benefit from buy backs but that looks impressive.
speedsgh: Yes, it would appear that the benefits of the attractive dividend policy have been more than nullified by NAV performance where IBT has noticeably lagged its peers over the past 5yrs. It would certainly be pleasing to see that change. The irony of course is that the discount to NAV has narrowed significantly over the same time period.
mozy123: Quite disappointing, other healthcare/bio trusts on the move over the last few months. IBT nothing. Nothing for a fair few years, hopefully a rocket has been ignited somewhere in the portfolio.
speedsgh: Dividends, buybacks, share issuance and discount I am pleased to report that the Company's fifth and sixth dividend payments were made during the financial year. We paid out a dividend equal to 4% of NAV as at 31 August 2018 in two equal tranches on 31 January 2019 and 31 August 2019, equating to a 4.1% increase when compared with dividend payments in the previous year. In accordance with the Shareholder Circular dated 13 September 2016 and as a matter of best practice, the Board will be seeking Shareholder approval to continue the payment of dividends and a resolution will be put to Shareholders at the forthcoming Annual General Meeting (AGM)...
shieldbug: IBT hit by pound strengthening and dividend payout?
speedsgh: According to the most recent monthly factsheet, the NAV as at financial year end on 31/8/2019 was £239m (622p per share). HTTPS:// Current dividend policy is to pay out an amount eqivalent to 4% of yr end NAV in two tranches. NAV as at 31/8/2018 was 699p which equated to a dividend of 28.0p in the current FY (2 x 14.0p payments) If NAV as at 31/8/2019 was 622p, this would appear to equate to a dividend of 24.75-25.0p over the next 12 months, which would represent a reduction of c.11-12%.
davebowler: QuoteData- Beating the odds view report Strategic positioning in mid-2018 helped International Biotechnology Trust (IBT) beat its benchmark over the past six months and close its discount to net asset value (NAV). This continued its outperformance of the US Nasdaq Biotechnology Index (NBI) over three and five years. Active management of the portfolio and an increased focus on larger mid-caps played out well in terms of IBT’s performance versus its peers. IBT’s manager is maintaining its established policy of active risk mitigation, designed to avoid exposure to binary events that can cause large swings in the share price (typically the results of the Phase III trials that provide the final confirmation of safety and efficacy before the FDA approves a treatment for marketing). This should be seen as another attraction to investors in the trust. IBT’s shares have recently moved to trade at a premium to NAV and it has been issuing stock, expanding the fund. SECTOR: SECTOR SPECIALIST - BIOTECHNOLOGY AND HEALTHCARE TICKER: IBT LN BASE CURRENCY: GBP (PENCE) PRICE: 634.00P NAV: 636.40P PREMIUM/(DISCOUNT): (0.4%) YIELD: 4.4% spacer spacer spacer ACCESS TO THE FAST-GROWING BIOTECH SECTOR charticon spacer spacer spacer spacer IBT is the longest-established of the London-listed funds specialising in the biotech/healthcare sector. It aims to achieve long-term capital growth by investing in biotechnology and other life sciences companies, and offers investors the highest yield in the sector while keeping its day-to-day running costs low. The portfolio is invested primarily in quoted companies, but IBT also has some exposure to unquoted compani
tomps2: Here's IBTs presentation at Mello London 2018, given by Carl Harald Janson, Lead Investment Manager. A comprehensive overview of the IT, which gives insight to the biotech sector, the growth drivers, the investment process at IBT, risk and how handled. Https://
International Biotechnol... share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210305 16:54:15